NLS Pharmaceutics and Kadimastem Form Strategic Alliance to Boost Gene-Edited Therapies

Strategic Collaboration to Advance Gene-Edited Cell Therapies

On October 27, 2025, NLS Pharmaceutics Ltd. (Nasdaq: NLSP), a Swiss biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST), an Israeli biotechnology firm, announced a pivotal partnership with TargetGene Biotechnologies Ltd. This collaboration aims to revolutionize cell-based treatments for severe health conditions, focusing on the development of next-generation gene-edited cell therapies.

Enhancing Cell Therapy Platforms

The Memorandum of Understanding (MOU) signed by the companies is designed to foster collaboration in developing and refining gene-edited cell therapy products. This partnership will combine Kadimastem's proprietary cell therapy programs, including AstroRx® and IsletRx, with TargetGene's advanced DNA-guided gene-editing technology, which allows for precise genome modifications while minimizing off-target risks.

As Kadimastem progresses toward merging with NLS Pharmaceutics, the new entity will operate under the name NewCelX. This merger signifies a crucial step forward in both companies’ missions to enhance their therapeutic offerings and expand their pipelines for treating challenging diseases, such as Amyotrophic Lateral Sclerosis (ALS) and diabetes.

Joint Development Goals

The collaboration intends to leverage joint research and development efforts, technology sharing, and future licensing opportunities. Through this synergy, NLS, Kadimastem, and TargetGene collectively aim to expedite the creation of scalable, commercially viable cell treatments that could change the landscape of current therapeutic approaches.

Yoel Shiboleth, the CEO of TargetGene, shared an optimistic vision regarding the partnership: "Our collaboration with Kadimastem will propel the evolution of cell-based medicine by merging our precision gene-editing technologies with their established stem cell platforms, enabling the creation of safer and more effective therapies tailored for prolonged patient benefits."

Prof. Michel Revel, Chief Scientist and Founder of Kadimastem, expressed excitement about the innovative potential of merging precise gene editing with stem-cell-derived therapeutic cells. He believes that this collaboration will lead to enhanced survival and efficacy of the modified cells when deployed in patients suffering from degenerative diseases like ALS.

Future Implications and Vision

This partnership marks a significant leap forward in Kadimastem's commitment to pursuing curative solutions for debilitating diseases. By combining advanced stem cell technology with TargetGene's innovative genome editing tools, the companies aim to engineer resilient, effective therapies that could redefine standards in regenerative medicine.

Ronen Twito, Executive Chairman of Kadimastem, emphasized the additions this collaboration brings to their overall mission: "We are excited to collaborate with TargetGene to develop next-gen cell therapies that improve treatment efficacy and safety for our patients."

As these companies position themselves at the forefront of innovative treatment, the medical community is eagerly watching their advancements. If successful, the therapies generated through this collaboration could provide breakthrough options for patients with conditions like ALS and diabetes, transforming traditional approaches into dynamic, effective treatments.

About NLS Pharmaceutics

NLS Pharmaceutics is dedicated to developing groundbreaking therapies for central nervous system disorders. Their commitment to enhancing patient outcomes is reflected in their focused research efforts and innovative product pipelines. To learn more, visit NLS Pharmaceutics.

About Kadimastem

Kadimastem stands at the forefront of clinical-stage cell therapy, pioneering allogeneic, stem cell-based treatments that aim to address severe diseases. For more information, explore Kadimastem.

About TargetGene

TargetGene Biotechnologies is an Israeli company recognized for its innovative gene-editing technologies, focusing on breakthroughs that provide safer, more effective modifications for treating genetic and chronic conditions.

Conclusion

The collaboration between NLS Pharmaceutics, Kadimastem, and TargetGene is poised to create a transformative effect in the field of medical treatments, particularly in developing efficient and sustainable solutions for challenging diseases.